人民财讯8月11日电，华东医药（000963）8月11日晚间公告，8月8日，公司全资子公司华东医药(杭州) 有限公司(简称"华东医药杭州")与江苏威凯尔医药科技股份有限公司(简称"江苏威凯尔")就VC005达成的 独家商业化合作协议正式生效。华东医药杭州获得江苏威凯尔的VC005口服剂型于中国大陆的独家商业 化许可权利。华东医药杭州将向江苏威凯尔支付5000万元首付款，以及最高不超过1.8亿元的注册里程 碑付款。 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-078 华东医药股份有限公司 关于全资子公司签署产品独家商业化合作协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概况 2025 年 08 月 08 日，华东医药股份有限公司（以下简称 "本公 司"或"公司"）全资子公司华东医药（杭州）有限公司（以下简称"华 东医药杭州"）与江苏威凯尔医药科技股份有限公司（以下简称"江苏 威凯尔"）就 VC005 达成的独家商业化合作协议正式生效。华东医药 杭州获得江苏威凯尔的 VC005 口服剂型（以下简称"许可产品"或"标 的产品"）于中国大陆（以下简称"许可区域"）的独家商业化许可权利。 华东医药杭州将向江苏威凯尔支付 5,000 万元人民币首付款，以及最 高不超过 1.8 亿元人民币的注册里程碑付款。 本次交易按照公司投资审批程序进行了评审和决策。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。根据深交所《股票上市规则》的规定， 本次交易的决策权限在公司董事会授权范围内，无需提交公司股东会 审议。 ...

华东医药公告，全资子公司华东医药杭州与江苏威凯尔签署独家商业化合作协议，获得VC005口服剂型 于中国大陆的独家商业化许可权利。华东医药杭州将向江苏威凯尔支付5000万元人民币首付款，以及最 高不超过1.8亿元人民币的注册里程碑付款。VC005片为新型、强效、高选择性的Ⅱ代口服JAK1抑制 剂，临床开发用于治疗炎症与自免疾病，已处于中重度特应性皮炎Ⅲ期临床阶段。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the acceleration of PD-(L)1/VEGF and PD-(L)1/IL-2 dual antibodies, confirming the trend of upgrading single antibodies to multi-target therapies [5][14] - As of August 8, 2025, there are 32 PD-(L)1 tri-antibodies in clinical and preclinical stages globally, with 16 being PD-(L)1/VEGF tri-antibodies [5][14] - The report emphasizes the potential of PD-1/VEGF/IL-2 tri-target combination therapies to exhibit superior synergistic treatment effects [30][39] Summary by Sections Section 1: PD-(L)1 Dual Antibody Upgrades - The report notes the upgrade of PD-(L)1 dual antibodies, with 6 PD-(L)1/VEGF tri-antibodies entering clinical trials [5][14] - Multiple PD-(L)1/VEGF tri-antibodies show superior preclinical efficacy compared to competitors [6][16] - The PD-1/VEGF/IL-2 tri-target combination is expected to demonstrate enhanced synergistic treatment effects [30][39] Section 2: Market Performance - In the second week of August, the pharmaceutical and biotechnology sector declined by 0.84%, underperforming the CSI 300 index by 2.07 percentage points [41][46] - The medical consumables sector showed the largest increase, while the medical research outsourcing sector experienced the largest decline [46][47] Section 3: Recommended and Benefiting Companies - Recommended companies in pharmaceuticals and bioproducts include: Heng Rui Medicine, East China Pharmaceutical, Sanofi, and others [8] - CXO companies include WuXi AppTec, Tigermed, and others [8] - Companies in medical devices include Mindray Medical, United Imaging, and others [8]

Core Viewpoint - The recent Phase II clinical trial results of HDM1002, an oral GLP-1 receptor agonist developed by the company, demonstrate significant weight loss and metabolic improvement, with good safety and tolerability, providing a strong basis for further clinical research [2][5]. Group 1: Clinical Trial Results - The Phase II clinical trial involved 185 participants and lasted 16 weeks, assessing the safety and efficacy of HDM1002 in overweight or obese individuals without diabetes [2]. - After 12 weeks of treatment, the percentage change in body weight from baseline for the HDM1002 100 mg BID, 200 mg BID, 400 mg QD, and placebo groups were -4.63%, -6.08%, -6.83%, and -2.88% respectively, with the 200 mg BID and 400 mg QD groups showing statistically significant differences compared to the placebo [3]. - The proportion of participants in the 200 mg BID and 400 mg QD groups who experienced a weight loss of ≥5% was 63.0% and 56.5%, respectively, both significantly higher than the placebo group [3]. Group 2: Safety and Tolerability - Most treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) were mild, with no severe adverse events reported [5]. - The most common TEAEs in the HDM1002 groups were gastrointestinal events, including nausea, vomiting, and diarrhea, all of which were mild to moderate in severity [5]. Group 3: Future Development and Product Pipeline - The successful results of the Phase II trial mark an important milestone in the development of HDM1002, which is now progressing to Phase III clinical research [5]. - The company has established a comprehensive and differentiated product pipeline around the GLP-1 target, including both oral tablets and injectables, with ongoing clinical trials for various innovative drugs [5].

Core Viewpoint - Huadong Medicine's stock price experienced a decline of 1.32% on August 8, closing at 42.47 yuan, with a trading volume of 355 million yuan [1] Company Overview - Huadong Medicine operates in three main sectors: pharmaceutical manufacturing, pharmaceutical commerce, and medical aesthetics [1] - The company's core products include Bailin capsules and Indomethacin tablets, with a focus on oncology, diabetes, and immunosuppressants [1] - The wholly-owned subsidiary, Sino-American Huadong, holds a patent for the crystal form of Indomethacin tablets, which is protected until 2040 [1] Recent Developments - Sino-American Huadong is actively defending its patent rights for Indomethacin tablets, resulting in seven pharmaceutical companies being suspended from purchasing the product due to patent disputes [1] - The National Intellectual Property Administration has ruled to maintain the validity of the involved patents against several invalidation requests [1] - Due to the patent disputes, Indomethacin tablets were not included in the 11th batch of national drug procurement [1] Financial Activity - On August 8, Huadong Medicine saw a net outflow of 4.4782 million yuan in principal funds, while the cumulative net inflow over the past five days reached 9.757 million yuan [1]

Core Points - The Shanghai Municipal Medical Procurement Management Office has suspended the procurement qualifications of certain drugs, including indobufen tablets produced by Shandong Modern Pharmaceutical Technology Co., Ltd due to patent disputes [1][2] - A total of seven companies have been suspended from procuring indobufen tablets since 2024, indicating a significant impact on the market [2][3] Industry Overview - Indobufen tablets, a new type of antiplatelet drug, were first developed by Farmitalia Carlo Erba in Italy and have become a substitute for patients intolerant to aspirin due to their lower side effects [2] - The sales of indobufen tablets have seen substantial growth, with sales reaching over 1 billion yuan in 2022 and projected to exceed 1.6 billion yuan in 2024, reflecting an 18.12% year-on-year increase [3] Patent and Legal Issues - The core patent for indobufen, covering specific crystal forms and their preparation methods, was granted to a subsidiary of Huadong Medicine, which has initiated extensive legal actions against other companies for patent infringement [4] - Indobufen tablets were excluded from the 11th batch of national procurement due to high patent infringement risks, despite meeting procurement conditions [5]

分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药的李前伦、灵康药业的隋国平、海 正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈锡飞为行业唯一一 个拥有博士学历的专职董秘。 从薪酬分 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药（维权）的李前伦、灵康药业（维 权）的隋国平、海正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈 锡飞为行业唯一一个拥有博士学历的专职 ...

Core Viewpoint - The launch of China's first pharmaceutical ETF fund aims to provide investors with exposure to leading companies in the chemical, biological, and traditional Chinese medicine sectors, capitalizing on the growth potential driven by innovation and demographic trends [1][5]. Industry Overview - The pharmaceutical industry is characterized by its essential nature, driven by a large population, aging demographics, and increasing GDP per capita, which supports long-term growth [5]. - By 2024, the proportion of the population aged 65 and above in China is expected to reach 15.6%, indicating a shift into a moderately aging society, which will further expand the pharmaceutical market [5]. Innovation and Growth - Innovative drugs are seen as a key driver for the pharmaceutical industry's growth, with the potential to unlock new value and re-evaluate medical asset worth [5]. - Domestic innovative drugs are anticipated to experience significant growth in 2024, supported by various internal and external factors, potentially leading to a "Davis Double Play" scenario [5]. - The integration of AI in drug development is expected to accelerate the research and development of new medications [5]. ETF Fund Details - The newly launched ETF fund (A class: 024985 / C class: 024986) will exclusively track the CSI Pharmaceutical Index, which includes leading companies in the chemical, biological, and traditional Chinese medicine sectors [1][19]. - The fund aims to provide a balanced investment approach, combining high-growth innovative drugs with more stable traditional Chinese medicine to mitigate volatility [1][19]. Performance Metrics - The pharmaceutical index has shown a significantly smaller decline compared to similar indices over the past five years, with positive returns over the last three years [14]. - The index's long-term annualized volatility and maximum drawdown are notably lower than those of comparable indices, indicating a more stable investment profile [14]. Key Constituents - The top ten constituents of the pharmaceutical index include major companies such as Heng Rui Medicine (14.91% weight), Pian Zai Ye (5.83%), and Yunnan Baiyao (4.81%), reflecting a diverse representation across the pharmaceutical sectors [13].